Dr. Corinne Beinat completed her PhD in Medicinal Chemistry at the University of Sydney in 2014 focusing on the development of novel small molecule therapeutics for the treatment of neurological disease. She then completed her postdoctoral training with Dr. Sanjiv Sam Gambhir in radiochemistry and molecular imaging before joining the department as an Instructor in 2019 and then as an Assistant Professor in 2022.

For over a decade, her research has explored the development of small molecules as therapeutics and imaging agents for various biological targets – an area at the interface of chemistry, pharmacology, cancer biology, and medicine. The overall goal of her research is to improve our knowledge, diagnosis, and treatment of cancer through the development of novel molecular imaging and treatment strategies.

The focus of Dr. Beinet's lab's research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. They then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. The lab additionally develops novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Their overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.